Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Display options

Format

Share it on

Full text links

Antimicrob Agents Chemother. 1985 Nov;28(5):648-53. doi: 10.1128/AAC.28.5.648.

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Antimicrobial agents and chemotherapy

M J Humphrey, S Jevons, M H Tarbit

PMID: 3004323 PMCID: PMC176350 DOI: 10.1128/AAC.28.5.648
Free PMC Article

Abstract

The pharmacokinetic profile of UK-49,858 (fluconazole), a novel triazole antifungal agent which is being developed for oral and intravenous use, was determined in mice, rats, dogs, and humans. Comparative data following oral and intravenous administration showed that bioavailability was essentially complete in all four species. Peak concentrations in plasma of drug normalized to a 1-mg/kg dose level following oral administration, were relatively high: 0.7, 0.6, 1.1, and 1.4 micrograms/ml in mice, rats, dogs, and humans, respectively. The volumes of distribution ranged between 1.1 liter/kg in mice and 0.7 liter/kg in humans, which are approximate to the values for total body water. Whole body autoradiography studies in mice following intravenous administration of [14C]UK-49,858 demonstrated that the drug was evenly distributed throughout the tissues, including the central nervous system and the gastrointestinal tract. Plasma protein binding was low (11 to 12%) in all species. Marked species differences were observed in elimination half-lives, with mean values of 4.8, 4.0, 14, and 22 h in mice, rats, dogs, and humans, respectively. The major route of elimination of the drug was renal clearance, with about 70% of the dose being excreted unchanged in the urine in each species. Studies with [14C]UK-49,858 on metabolism and excretion (intravenous and oral) in mice and dogs showed that about 90% of the dose was recovered as unchanged drug in urine and feces, confirming the metabolic stability of the drug. This pharmacokinetic profile is markedly different from that of imidazole antifungal drugs and undoubtedly contributes to the excellent efficacy of UK-49,858 in vivo.

Cited by

Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis.

Murakoso K, Minagawa R, Echizen H.
J Pharm Health Care Sci. 2018 Mar 20;4:5. doi: 10.1186/s40780-018-0103-5. eCollection 2018.
PMID: 29568540

Antifungal Resistance Regarding .

Peano A, Johnson E, Chiavassa E, Tizzani P, Guillot J, Pasquetti M.
J Fungi (Basel). 2020 Jun 25;6(2). doi: 10.3390/jof6020093.
PMID: 32630397

Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong.

Seneviratne CJ, Rajan S, Wong SS, Tsang DN, Lai CK, Samaranayake LP, Jin L.
Front Microbiol. 2016 Feb 26;7:216. doi: 10.3389/fmicb.2016.00216. eCollection 2016.
PMID: 26955369

Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Yeh E, Brown G.
Can J Hosp Pharm. 2009 Nov;62(6):457-63. doi: 10.4212/cjhp.v62i6.843.
PMID: 22478933

Comparative study of the effectiveness of oral fluconazole and intravaginal clotrimazole in the treatment of vaginal candidiasis.

Mikamo H, Izumi K, Ito K, Tamaya T.
Infect Dis Obstet Gynecol. 1995;3(1):7-11. doi: 10.1155/S1064744995000238.
PMID: 18475414

Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy.

Sakamoto Y, Isono H, Enoki Y, Taguchi K, Miyazaki T, Kunimoto H, Koike H, Hagihara M, Matsumoto K, Nakajima H, Sahashi Y, Matsumoto K.
J Fungi (Basel). 2021 Nov 16;7(11). doi: 10.3390/jof7110975.
PMID: 34829262

Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Yeh E, Brown G.
Can J Hosp Pharm. 2009 Nov;62(6):457-63. doi: 10.4212/cjhp.v62i6.843.
PMID: 22478933

Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model.

Chesdachai S, Rajasingham R, Nicol MR, Meya DB, Bongomin F, Abassi M, Skipper C, Kwizera R, Rhein J, Boulware DR.
Open Forum Infect Dis. 2019 Oct 01;6(10). doi: 10.1093/ofid/ofz369.
PMID: 31420668

Fluconazole (Diflucan).

Hollier LM, Cox SM.
Infect Dis Obstet Gynecol. 1995;3(6):222-5. doi: 10.1155/S1064744995000676.
PMID: 18476045

Prediction and Characterization of CYP3A4-mediated Metabolisms of Azole Fungicides: an Application of the Fused-grid Template* system.

Yamazoe Y, Yamada T, Nagata K.
Food Saf (Tokyo). 2020 Jun 26;8(2):34-51. doi: 10.14252/foodsafetyfscj.D-20-00010. eCollection 2020 Jun.
PMID: 32626635

Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers.

Dhondt L, Croubels S, De Paepe P, Wallis SC, Pandey S, Roberts JA, Lipman J, De Cock P, Devreese M.
Front Pharmacol. 2020 Jun 12;11:883. doi: 10.3389/fphar.2020.00883. eCollection 2020.
PMID: 32595506

References

Drugs. 1975;9(6):424-47 - PubMed
Postgrad Med J. 1974 Jul;50 Suppl 1:13-6 - PubMed
Arch Intern Med. 1977 Sep;137(9):1180-5 - PubMed
Antimicrob Agents Chemother. 1978 Jun;13(6):965-8 - PubMed
Drugs. 1978 Sep;16(3):177-201 - PubMed
J Chromatogr. 1979 Jan 11;168(1):117-24 - PubMed
Acta Radiol Suppl. 1954;118:1-110 - PubMed
Drugs. 1980 Jan;19(1):7-30 - PubMed
J Antimicrob Chemother. 1981 Oct;8(4):299-304 - PubMed
Antimicrob Agents Chemother. 1982 Jan;21(1):151-8 - PubMed
Chemotherapy. 1982;28 Suppl 1:37-42 - PubMed
Clin Pharmacokinet. 1983 Jan-Feb;8(1):17-42 - PubMed
Antimicrob Agents Chemother. 1985 May;27(5):832-5 - PubMed
Postgrad Med J. 1979 Sep;55(647):657-61 - PubMed

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Abstract

Similar articles

Cited by

References

Substances

MeSH terms

Publication Types

LinkOut - more resources